

# Kexing Biopharm

**EU/FDA GMP PRODUCTS**

Precise Products  
Predictable Effects  
Health Protection





## A leader in China recombinant protein the rapapeutics industry

Kexing Biopharm (Stock Code: 688136) is a leading multinational biopharmaceutical company specializing in the research, manufacture, and commercialization of innovative medicines combining recombinant proteins, antibodies, and next generation cell and gene therapies. Harnessing proprietary technology platforms, Kexing pioneers novel targeted biological therapies and advanced drug delivery systems to address critical unmet needs in oncology, autoimmune and infectious diseases, making transformative impact on patients. Driven by a dual strategic focus on breakthrough innovation and global outreach, Kexing is committed to becoming a world-class leader in bringing high-quality pharmaceutical solutions to patients worldwide.

Kexing Biopharm offers a diversified portfolio of 30 innovative products, including drugs "Human Erythropoietin Injection (EPOSINO)", "Human Interferon  $\alpha$ 1b for Injection (SINOGEN)" and "Human Granulocyte Colony-stimulating Factor Injection (WHITE-C)"; microecological agents, notably "Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO)"; targeted drugs, such as "Albumin-bound Paclitaxel (Apexelsin)" and "Infliximab for Injection (Reminton)". Our core products outperform competitors' options in China, with SINOGEN and EPOSINO leading positions in their respective therapeutic categories, consistently securing the top two rankings in market share. Our products are supplied to over 20,000 sales terminals across China, including over 8,000 hospitals, 7,700 third-party terminals, and over 3,000 pharmacies. In addition, we have established 6 overseas subsidiaries, which have acquired market access and achieved sales in over 70 countries and regions such as the European Union, Brazil, Philippines and Indonesia. In recent years, we also have created a high-quality biopharmaceuticals overseas platform based on the concept of "Global Product Selection + Global Product Coverage", and secured commercial partnerships with numerous renowned pharmaceutical companies worldwide by leveraging its global marketing infrastructure, targeted market penetration strategies, and commitment to delivering premium-quality products and services.

Kexing Biopharm operates multiple R&D centers, such as the Shenzhen Medical Research Institute, the Shandong R&D Center and the Guangzhou R&D Center. It boasts an R&D team of nearly 200 members, with over 60% holding master's degrees or higher. At present, it has obtained 65 patents. The Company has established a complete drug R&D and innovation system with three major biotechnology systems: Prokaryotic cell technology, eukaryotic cell technology, and viable bacteria technology. Depending on these systems, it has built several leading technology platforms worldwide, such as KX-FUSION Fusion Protein Technology Platform, KX-BODY Antibody Technology Platform, K'Exosome Delivery Technology Platform, Vector Vaccine Technology Platform, and Microecological Agent R&D and Industrialization Technology Platform.

The Company focuses on biopharmaceuticals and implements a strategic R&D plan that enables a tiered, serial, and graduated product portfolio. Our short-term efforts are concentrated on in-depth development around new formulations, new indications and long-acting effects for recombinant protein therapeutics. In the medium and long term, we focus on fields such as oncology, immunology and degenerative diseases, with plans to develop new antibodies, proteins and nucleic acid drugs. It boasts robust pipelines of innovative drugs and dozens of projects currently under development, including GB05 Human Interferon  $\alpha$ 1b Inhalation Solution (Phase III clinical trial), GB-K02 Long-acting Human Granulocyte Colony-stimulating Factor Injection (Phase III clinical trial), GB08 Long-acting Growth Hormone (completed Phase I clinical trial), GB10 (target: VEGF/ANG-2) for fundus diseases, GB12 (target: IL-4R/IL-31(R)) for atopic dermatitis, GB18 (target: GDF-15) for cancer cachexia, GB23 (target: IFN/GPC3/PD1) for solid tumors, GB24 (target: TL1A, bispecific antibody) for inflammatory bowel diseases, and GB25 (tri-specific antibody) for colorectal cancer.

Following the mission of "Precise Products, Predictable Effects, Health Protection", we are devoted to providing patients with biotechnology and becoming the leader in high-quality biologics!

# Infliximab



Kexing  
Biopharm

**ACTIVE SUBSTANCE** Infliximab

**STRENGTH** 100 mg

**FORM** Sterile, white to off-white lyophilized powder

**STORAGE** Store in a refrigerator (2 °C-8 °C)

**ADMINISTRATION** Intravenous (IV) infusion after reconstitution

**CONTAINER** 100 mg of infliximab in a single-dose vial



\* The packaging effect is for reference only, please refer to the actual packaging of the drug on the market.

## • INDICATIONS •

Rheumatoid Arthritis (RA)

Ankylosing spondylitis (AS)

Psoriasis (Ps)

Crohn's Disease (CD)

Pediatric Crohn's Disease

Ulcerative Colitis (UC)

Pediatric Ulcerative Colitis

Psoriatic Arthritis (PsA)


The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: guolei01@kexing.com**

# Ahrasin<sup>®</sup>

# Adalimumab



Kexing  
Biopharm



## ACTIVE SUBSTANCE

Adalimumab

## STRENGTH

100mg/mL 0.4mL

## FORM

Prefilled pen

## STORAGE

Store in a refrigerator (2 °C-8 °C)

## ADMINISTRATION

Subcutaneous injection (SC)

## CONTAINER

100mg/mL 0.4mL in a single-dose pen

\* The packaging effect is for reference only, please refer to the actual packaging of the drug on the market.

## • INDICATIONS •

Rheumatoid Arthritis (RA)

Ankylosing spondylitis (AS)

Psoriasis (Ps)

Crohn's Disease (CD)

Juvenile idiopathic arthritis (JIA)

Uveitis (UV)

Hidradenitis Suppurativa (HS)

Ulcerative Colitis (UC)

Psoriatic Arthritis (PsA)

The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: guolei01@kexing.com**

# Pembrolizumab



Kexing  
Biopharm

## ACTIVE SUBSTANCE

Pembrolizumab

## STRENGTH

100 mg

## FORM

Concentrate for solution for infusion

## STORAGE


Store in a refrigerator (2 °C-8 °C)

## ADMINISTRATION

Intravenous use after dilution

## CONTAINER

4 mL of concentrate in a 10 mL clear glass vial



\* The packaging effect is for reference only, please refer to the actual packaging of the drug on the market.

## • INDICATIONS •

|                                                             |                                                                                     |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Melanoma                                                    | Non-small cell lung carcinoma (NSCLC)                                               |
| Malignant pleural mesothelioma (MPM)                        | Classical Hodgkin lymphoma (cHL)                                                    |
| Urothelial carcinoma                                        | Head and neck squamous cell carcinoma (HNSCC)                                       |
| Renal cell carcinoma (RCC)                                  | Biliary tract carcinoma (BTC)                                                       |
| Oesophageal carcinoma                                       | Triple-negative breast cancer (TNBC)                                                |
| Endometrial carcinoma (EC)                                  | Cervical cancer                                                                     |
| Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma | Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers |

The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: guolei01@kexing.com**

# Omalizumab



Kexing  
Biopharm


**ACTIVE SUBSTANCE** Omalizumab

**STRENGTH** 75 mg; 150 mg; 300 mg

**FORM** Solution for injection in pre-filled syringe/pre-filled pen

**STORAGE** Store in a refrigerator (2°C-8°C). Store in the original package in order to protect from light.

**ADMINISTRATION** For subcutaneous (SC) administration only



\* The packaging effect is for reference only, please refer to the actual packaging of the drug on the market.

## • CONTAINER •

**75 mg** Prefilled syringes (0.5 mL solution), prefilled pens (0.5 mL solution)

**150 mg** Prefilled syringes (1 mL solution), prefilled pens (1 mL solution)

**300 mg** Prefilled syringes (2 mL solution), prefilled pens (2 mL solution)

## • INDICATIONS •

Asthma

Chronic rhinosinusitis with nasal polyps (CRSwNP)

IgE-Mediated Food Allergy

Chronic Spontaneous Urticaria

The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: guolei01@kexing.com**



Kexing  
Biopharm

# Tocilizumab

## ACTIVE SUBSTANCE

Tocilizumab

## STRENGTH

SC: 162mg/0.9mL

## FORM


SC: Solution for injection in single-dose prefilled syringe or single-dose prefilled ACTPen®

## STORAGE

Store in a refrigerator (2°C- 8°C)

## ADMINISTRATION

SC



\* The packaging effect is for reference only, please refer to the actual packaging of the drug on the market.

## CONTAINER

### SC Injection

162 mg/0.9 mL clear, colorless to slightly yellowish solution in a single-dose prefilled syringe or single-dose prefilled ACTPen® autoinjector.

The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: guolei01@kexing.com**

Tocilizumab is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

► **Rheumatoid Arthritis (RA)**

Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

---

► **Giant Cell Arteritis (GCA)**

Adult patients with giant cell arteritis.

---

► **Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)**

Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

---

► **Polyarticular Juvenile Idiopathic Arthritis (PJIA)**

Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

---

► **Systemic Juvenile Idiopathic Arthritis (SJIA)**

Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

---

► **Cytokine Release Syndrome (CRS)**

Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.

---

► **Coronavirus Disease 2019 (COVID-19)**

Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

---

The above information is all brief prescribing information. For more detailed content and cooperation proposal, **please contact: [guolei01@kexing.com](mailto:guolei01@kexing.com)**



**KEXING BIOPHARM CO., LTD.**

Tel:0086-531-55763601/02/03      E-mail: [sales@kexing.com](mailto:sales@kexing.com)

Website:[www.kexingbiopharm.com](http://www.kexingbiopharm.com)